Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences

American Journal of Human Genetics

Volumn 60, Issue 2, 1997, Pages 284-295

  Sachse, Christoph ^a   Brockmöller, Jürgen ^a   Bauer, Steffen ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE; DEXTROMETHORPHAN;

ADULT; ALLELE; ARTICLE; CAUCASIAN; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENE LOCATION; GENETIC LINKAGE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN VARIANT;

EID: 0031038038     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Agúndez JAG, Ledesma MC, Ladero JM, Benítez J (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265-269
2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446
3. Appanna G, Tang BK, Müller R, Kalow W (1996) A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate. Drug Metab Dispos 24:303-306
4. Benet LZ, Kroetz DL, Sheiner LB (1996) Pharmacokinetics. In: Hardman JG, Goodman Gilman A, Limbird LE (eds) Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. McGraw-Hill, New York, pp 3-27
5. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29:192-209
6. Brockmöller J, Roots I (1994) Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 27:216-248
7. Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558
8. Chen ZR, Somogyi AA, Bochner F (1990) Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 12:97-104
9. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520
10. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1:33-41
11. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, et al (1996a) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201
12. Daly AK, Fairbrother KS, Andreassen OA, London SJ, Idle JR, Steen VM (1996b) Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 6:319-328
13. Daly AK, Leathart JB, London SJ, Idle JR (1995) An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet 95:337-341
14. Dixon WJ (1992) BMDP statistical software manual. University of California Press, Berkeley
15. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187
16. 1795 in exon 3 generates a premature stop codon. Pharmacogenetics 4:271-274
17. _ (1994b) A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn Schmiedebergs Arch Pharmacol 350:434-439
18. 450 CYP2D locus. Nature 347: 773-775
19. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532
20. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829
21. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355
22. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ (1989) The human debrisoquin 4-hydroxylase (CYP2D) locus: sequence and isolation of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889-904
23. Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 133:161-166
24. Løvlie R, Daly AK, Molven A, Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30-34
25. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586
26. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M (1993) Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 3: 275-280
27. Panserat S, Mura C, Gérard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R (1995) An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Pharmacol 40: 361-367
28. 226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 6:269-272
29. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2d ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
30. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, et al (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 3:923-926
31. Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 38:618-624
32. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85:5240-5243
33. Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, Gulbrandsen A-K (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-223
34. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brøgger A, Børresen AL (1994) Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 4:47-57
35. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, et al (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1:26-32